Drug intelligence / Profile preview

REC625

Development stage: Preclinical
Lead developer: Recbio
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

REC625 is a novel adjuvanted recombinant respiratory syncytial virus (RSV) vaccine candidate. It incorporates the proprietary adjuvant BFA01, which is designed to enhance immune response. The vaccine is being developed for the prevention of RSV infection, a significant cause of respiratory illness in infants, young children, and older adults. REC625 is under development by Jiangsu Recbio Technology[3].

Targets

RSV F (Respiratory syncytial virus fusion protein)

Beyond the preview

Go deeper on REC625.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on REC625.

Explore the full profile